Abstract
Visceral leishmaniasis (VL) is a parasitic disease caused by the protozoan Leishmania (L.) infantum. In Brazil, the number of cases of the disease has increased in the last years. The treatment of leishmaniasis in Brazil consists of the use of pentavalent antimonials and amphotericin B. Recently, miltefosine has been shown to be highly effective against VL in Asia. Although, this drug is not used in the treatment of VL in Brazil, miltefosine is approved for use in the treatment of canine visceral leishmaniasis (CVL). In this study, we evaluate the susceptibility to miltefosine in vitro of isolates of L. (L.) infantum from dogs of municipality of Embu-Guaçu, located in the metropolitan region of the city of São Paulo.
Highlights
Visceral leishmaniasis is a parasitic disease caused by the protozoan L. (L.) infantum
Since Visceral leishmaniasis (VL) is zoonotic in Brazil, domestic dogs constitute the main reservoir for the parasite, playing an essential role in transmission of disease to humans
In canine visceral leishmaniasis (CVL), the only drug used for treatment is miltefosine, a drug already used in the treatment of VL in Southeast Asia
Summary
Visceral leishmaniasis is a parasitic disease caused by the protozoan L. (L.) infantum. Visceral leishmaniasis is a parasitic disease caused by the protozoan L. The disease is the most severe clinical form of leishmaniasis that can lead to death if it is not treated. In Brazil, about 3,000 new cases of the disease are reported annually, with an increasing number of cases in urban and periurban areas.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
